Joint Supplement Glucosamine Tied to Higher Dementia Risk

Most of us think of glucosamine as a harmless fix for creaky knees. New research suggests the story may be more complicated for people whose memory is already frayed.

Researchers at the University of Florida dug into medical records from more than 65,000 people, including roughly 24,000 diagnosed with dementia and 41,000 with mild cognitive impairment, a gray zone where memory or thinking problems exist but full dementia has not yet taken hold. About 8 percent of individuals in the dataset reported using glucosamine supplements. The analysis linked glucosamine use, in people who already had Alzheimer’s or other dementias, to a roughly 25 percent higher risk of death over five years. It also found that among those with mild cognitive impairment, taking glucosamine was associated with greater odds of progressing to dementia.

Numbers like these prompt obvious questions. Is glucosamine driving the decline? Or is it merely tagging along with other risk factors? The study does not prove cause and effect. It shows a pattern. A worrying pattern, yes, but not a smoking gun.

So how might a joint supplement influence the brain at all? Glucosamine is a basic building block for complex sugar chains known as glycans. These sugar decorations attach to proteins in a process called glycosylation, and they can change how proteins fold, move and function. Unlike many supplements that never reach the brain, glucosamine appears able to cross the blood-brain barrier, the body’s selective gatekeeper. In brains affected by Alzheimer’s, prior research has reported elevated levels of certain glycan attachments on proteins. Investigators hypothesize that extra sugar tagging may alter critical proteins in ways that worsen the disease process.

The team didn’t stop at human records. They turned to mice engineered to mimic Alzheimer’s-like pathology. When researchers dampened the activity of enzymes involved in producing those glycan tags, the animals’ symptoms improved. Conversely, giving glucosamine to mice already showing Alzheimer-like signs made memory problems worse. Importantly, healthy mice given the same doses showed no obvious change. That pattern hints that glucosamine’s effects may depend on the brain’s preexisting metabolic or pathological state.

What should people who take glucosamine for osteoarthritis or joint pain do now? The short answer: talk to your doctor before making changes. This study flags a potential risk in specific groups but does not establish that glucosamine causes dementia across the board.

This research does not prove causation; do not stop taking supplements without consulting a healthcare professional.

The bigger lesson is a reminder that even long-used, seemingly benign supplements can behave unpredictably in vulnerable bodies. With millions worldwide using glucosamine, researchers say more work is essential to untangle who might be at risk and why. Factors such as age, metabolic health, the stage of cognitive impairment and underlying brain chemistry could all shape the response. Future studies will need to test whether stopping glucosamine, altering dose, or targeting the glycan pathway directly changes cognitive outcomes.

The study appears in Nature Metabolism. It leaves a clear and uneasy question hanging: when a substance crosses the barrier meant to protect the brain, is it helping or harming—depends, it seems, on which brain it meets.